insulin glulisine vs SAR341402

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

SAR341402

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT03211858 · Phase 3 · completed

The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.

Reported efficacy

Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)

Result source: NCT03211858

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glulisineSAR341402
HbA1c, change-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858
Body weight, change (kg)0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
—Not reported
HbA1c below 7%22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858
Fasting plasma glucose, change—Not posted · NCT00135057-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858
3-point MACE (% with event)—Not posted · NCT00135057—Not reported

HbA1c, change

insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
SAR341402
-0.4% vs -0.3%vs NovoLog/NovoRapidwk 26 · n 301NCT03211858
1 other result
  • -0.3% vs -0.3% wk 52 · n 301 · Phase 3 · secondary NCT03211858

Body weight, change (kg)

insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
SAR341402
—Not reported

HbA1c below 7%

insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
SAR341402
19.6% vs 18.2%vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • 16.6% vs 14.5% wk 26 · n 301 · Phase 3 · secondary NCT03211858

Fasting plasma glucose, change

insulin glulisine
—Not posted · NCT00135057
SAR341402
-0.1 vs -0.3vs NovoLog/NovoRapidwk 52 · n 301NCT03211858
1 other result
  • -0.5 vs -0.2 wk 26 · n 301 · Phase 3 · secondary NCT03211858

3-point MACE (% with event)

insulin glulisine
—Not posted · NCT00135057
SAR341402
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin glulisine: 4 of 4 rows · SAR341402: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glulisineSAR341402
Dropout rate
23.5%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
12.3%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Discontinued due to AEs
2.6%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
2.7%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Serious AEs
11.9%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
12%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Most frequent reported AEs
a
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
nasopharyngitis 11.3%
upper respiratory tract infection 7.3%
influenza 5%
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glulisine

HbA1c Less Than 7% 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
absolute value · percentage points
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk
absolute change · mmol/L
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
Weight 0.46 vs 0.22 Insulin Glargine+Metformin+Glimepiride kg @ 24wk
absolute change · kg
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.5 vs 1.6 Insulin-lispro kg*
NCT01194258 · Phase 2 · registry result, not featured evidence · converted to kg from 3.35 pounds as posted
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

SAR341402

Fasting Plasma Glucose -0.49 vs -0.17 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
-0.1 vs -0.34 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
Daily Plasma Glucose -0.34 vs -0.53 NovoLog/NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3
show 1 more result
0.12 vs -0.18 NovoLog/NovoRapid mmol/L @ 52wk
NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · SAR341402's landscape